Cosmos Health Inc. (COSM) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Form 10-Q for Cosmos Health Inc. for the quarterly period ended March 31, 2026. Cosmos Health is an international healthcare group headquartered in Thessaloniki, Greece, operating in the nutraceuticals, pharmaceuticals, and healthcare distribution sectors. The company is classified as a Smaller Reporting Company and is not an emerging growth company. As of May 18, 2026, there were 54,428,491 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $17,927,892 | $13,712,528 |
| Gross Profit | $1,381,171 | $2,049,799 |
| Gross Margin | 7.7% | 15.0% |
| Net Loss | $(2,805,423) | $(818,097) |
| Net Loss Per Share (Basic/Diluted) | $(0.06) | $(0.03) |
| Operating Cash Flow | $(1,067,066) | $(186,316) |
| Cash & Restricted Cash (End of Period) | $2,158,921 | $742,881 |
| Total Debt (Current + Long Term) | $12,292,465 | $N/A |
Note: Total Debt includes Lines of Credit ($7.86M), Notes Payable ($3.45M), and Convertible Notes ($5.43M net of discounts).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 30.7% year-over-year, driven by expansion in wholesale distribution (Cosmofarm S.A.) and contract manufacturing (Cana S.A.).
- Margin Compression: Gross margin declined significantly from 15.0% to 7.7%. This was caused by a shift in revenue mix toward lower-margin wholesale distribution and a $375,337 revenue reversal related to the distributor Medihelm S.A. due to collectability concerns.
- Increased Net Loss: Net loss widened by 243% to $2.8 million. Key drivers included a $442,439 loss on digital assets (crypto), $390,350 in non-cash interest expense on convertible notes, and $313,157 in foreign currency transaction losses.
- Digital Assets: The company purchased $1.1 million in Bitcoin during the quarter. Total digital asset holdings (ETH and BTC) are carried at a fair value of $2.07 million, representing a cumulative unrealized loss of $1.03 million.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for 12 months from the filing date. The company relies on external financing to fund operations and meet debt obligations.
- Liquidity Strategy: The company raised approximately $1.83 million via its At-the-Market (ATM) program in Q1. It maintains a Securities Purchase Agreement for up to $300 million in senior secured convertible notes, with an initial $8 million tranche closed in August 2025.
- Strategic Initiatives: Plans include expanding the Sky Premium Life brand in the UAE, growing the Cosmofarm wholesale customer base, and strengthening contract manufacturing agreements.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and IT general controls (ITGCs). Remediation efforts are ongoing.
- Related Party Risks: Significant balances exist with related parties, including a fully impaired loan receivable from Doc Pharma S.A. ($3.95M allowance recorded in 2025) and substantial prepaid expenses.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of unrestricted cash ($514,702) versus restricted cash ($1.64M earmarked for crypto purchases) against upcoming debt maturities and operating burn rates.
- Medihelm S.A. Exposure: Assess the impact of the $1.33M cumulative revenue reversal and the collectability of remaining receivables from this key distributor.
- Digital Asset Volatility: Monitor the fair value of crypto holdings (ETH/BTC), which currently show a significant unrealized loss and contributed materially to the Q1 net loss.
- Debt Covenants: Review compliance with the August 2025 Convertible Note covenant requiring a minimum cash balance of $400,000 at quarter-end.
- Internal Control Remediation: Track progress on fixing material weaknesses in segregation of duties and IT controls to ensure future financial reporting reliability.